CN115362001A - Pick1的脂质缀合的肽抑制剂 - Google Patents

Pick1的脂质缀合的肽抑制剂 Download PDF

Info

Publication number
CN115362001A
CN115362001A CN202180027127.0A CN202180027127A CN115362001A CN 115362001 A CN115362001 A CN 115362001A CN 202180027127 A CN202180027127 A CN 202180027127A CN 115362001 A CN115362001 A CN 115362001A
Authority
CN
China
Prior art keywords
pick1
peptide
inhibitor
hwlkv
npeg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027127.0A
Other languages
English (en)
Chinese (zh)
Inventor
K·L·马德森
U·格特赫
N·R·克里斯滕森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Original Assignee
Københavns Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet filed Critical Københavns Universitet
Publication of CN115362001A publication Critical patent/CN115362001A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
CN202180027127.0A 2020-03-06 2021-03-05 Pick1的脂质缀合的肽抑制剂 Pending CN115362001A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20161493 2020-03-06
EP20161493.0 2020-03-06
PCT/EP2021/055678 WO2021176094A1 (en) 2020-03-06 2021-03-05 Lipid conjugated peptide inhibitors of pick1

Publications (1)

Publication Number Publication Date
CN115362001A true CN115362001A (zh) 2022-11-18

Family

ID=69780027

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027127.0A Pending CN115362001A (zh) 2020-03-06 2021-03-05 Pick1的脂质缀合的肽抑制剂

Country Status (10)

Country Link
US (1) US20230346948A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114524A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023506598A (cg-RX-API-DMAC7.html)
KR (1) KR20220150313A (cg-RX-API-DMAC7.html)
CN (1) CN115362001A (cg-RX-API-DMAC7.html)
AU (1) AU2021232645B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022017673A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168324A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011051A (cg-RX-API-DMAC7.html)
WO (1) WO2021176094A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008101160A2 (en) * 2007-02-16 2008-08-21 Genentech, Inc. Htra1-pdz and htra3-pdz modulators
WO2012156308A1 (en) * 2011-05-13 2012-11-22 Københavns Universitet (University Of Copenhagen) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
CN105828832A (zh) * 2013-12-01 2016-08-03 哥本哈根大学 Psd-95的二聚抑制剂的脂肪酸衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020083905A1 (en) 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008101160A2 (en) * 2007-02-16 2008-08-21 Genentech, Inc. Htra1-pdz and htra3-pdz modulators
WO2012156308A1 (en) * 2011-05-13 2012-11-22 Københavns Universitet (University Of Copenhagen) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
CN105828832A (zh) * 2013-12-01 2016-08-03 哥本哈根大学 Psd-95的二聚抑制剂的脂肪酸衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER TURNER,ET AL: "Administration of a novel high affinity PICK1 PDZ domain inhibitor attenuates cocaine seeking in rats", NEUROPHARMACOLOGY, vol. 164, no. 107901, 1 March 2020 (2020-03-01), pages 2 - 3 *

Also Published As

Publication number Publication date
BR112022017673A2 (pt) 2022-11-08
AU2021232645B2 (en) 2026-07-09
WO2021176094A1 (en) 2021-09-10
US20230346948A1 (en) 2023-11-02
AU2021232645A1 (en) 2022-09-15
CA3168324A1 (en) 2021-09-10
KR20220150313A (ko) 2022-11-10
EP4114524A1 (en) 2023-01-11
JP2023506598A (ja) 2023-02-16
MX2022011051A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
RU2531591C2 (ru) Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
US20140018300A1 (en) Neuroprotective and neurorestorative methods and compositions
US20250215052A1 (en) Inhibitors of pick1 and uses thereof
AU2019247467B2 (en) Compstatin analogs with increased solubility and improved pharmacokinetic properties
JP6032854B2 (ja) 抗新生物及び抗血管新生活性を有する環状ペプチド
JP7074673B2 (ja) エンドソーマルgタンパク質共役受容体のトリパータイト・モジュレーター
JP6549554B2 (ja) コレステロール流出を刺激する、減少した毒性を有するペプチド
US20220047512A1 (en) Methods and compositions for targeted delivery of protein fragments
US8673857B2 (en) Long term potentiation with cyclic-GluR6 analogs
KR101933543B1 (ko) 말초 신경 손상을 치료하기 위한 뉴레귤린의 용도
JP2015521636A (ja) in−vivoで神経変性疾患(特にアルツハイマー病)に活性なリポソーム
CN107406513B (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
ES2247329T3 (es) Prevencion de muerte celular utilizando segmentos de proteinas fibrilares neurales.
US8796215B2 (en) Neurotrophic peptides
ES2952367T3 (es) Conjugados terapéuticos basados en PAR-1 y usos de los mismos
US20230346948A1 (en) Lipid conjugated peptide inhibitors of PICK1
KR20220110278A (ko) 타우병증을 치료하기 위한 펩타이드 조성물 및 방법
HU231182B1 (hu) A ß-amiloid toxicitását gátló kis peptid inhibitorok
JP2023533407A (ja) 中枢神経系への分子輸送系
US20210000912A1 (en) Compositions And Methods For Prophylaxis Or Treatment Of Pain
EP3787661A1 (en) Compositions and methods for treating glioblastoma
WO2015105957A1 (en) Pten antagonist peptides and methods of using the same
WO2009153418A1 (fr) Peptides harp inhibant la croissance tumorale
HK1060851B (en) Preventing cell death using segments of neural thread proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination